Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Antiretroviral Strategy in Persistently Non-adherent Children, Adolescents, and Young Adults Who Are Failing HAART and Have the M184V Resistance Mutation.

NCT01338025 is registered in ClinicalTrials.gov with International Maternal Pediatric Adolescent AIDS Clinical Trials Group as lead sponsor.

NCT NCT01338025
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01338025 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of 3TC or FTC Mono-therapy Compared to Continuing HAART as a Bridging Antiretroviral Strategy in Persistently Non-adherent Children, Adolescents, and Young Adults Who Are Failing HAART and Have the M184V Resistance Mutation.
Lead sponsor
International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Phase
Phase 4
Overall status
Terminated
Start date
March 31, 2011
Completion date
May 31, 2013
Enrollment
33 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

hiv disease